|
|
|
|
|
by KSteffensen
434 days ago
|
|
The main problem with development of new antibiotics is not that it requires groundbreaking new science to be invented, but that there is no business case for it. Or at least the business case for spending your R&D on anti-obesity medicine looks a lot better. |
|
This inability to bring a product to market is in fact an artifact of the for-profit healthcare system.
Besides the obvious aspects of weight-loss and erectile-dysfunction drugs being more profitable, there is also an issue with imaginary property.
Pharma will not bring a drug to market unless they can own exclusive rights. Since this is a naturally occurring molecule, some tweak will need to be made before the chemical is eligible for a patent.
So until some company can make a custom modification, without disrupting the efficacy, it won't be considered a viable product.